Oaktree Capital Management has successfully closed its Life Sciences Lending Fund, securing a record-breaking $2.3 billion capital commitment. The fund aims to provide customized capital solutions to innovative companies in the life sciences sector, with a focus on high-growth areas like biopharma and medical devices. It prioritizes lending to companies with strong intellectual property, late-stage assets, and advanced manufacturing capabilities to mitigate risk.
What You Should Know:
- Oaktree Capital Management has closed its Life Sciences Lending Fund with a total capital commitment of $2.3B, representing the largest pool of capital ever raised dedicated to the space.
- Oaktree’s Life Sciences Lending Fund aims to generate attractive risk-adjusted returns by providing bespoke capital solutions to innovative companies across the life sciences sector globally, with a focus on high-growth subsectors, such as biopharma and medical devices.
- The Fund focuses on lending to companies with specific attributes, including those with diverse product portfolios comprised of late-stage assets targeting difficult-to-treat medical conditions, strong intellectual property and/or state-of-the-art manufacturing facilities, which, along with careful structuring, provides for adequate risk protection.
Source: HitConsultant
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.